Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
| ERICKSON AIR | EAC | 5.10% |
| ASSURED GUAR | AGO | 4.98% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Symmetry Surgical, a subsidiary of orthopedic implants and instruments maker Symmetry Medical Inc. (SMA - Analyst Report) recently inked an exclusive agreement in Italy with Biocommerciale Srl. Per the agreement, Biocomerciale will distribute Symmetry’s surgical instruments portfolio inclusive of all brands under erstwhile Codman Surgical Instruments, Olsen Medical and SSi.
Biocommerciale is driven to meet the demands of hospitals and healthcare professionals in Italy. With experience of more than 30 years and distribution network linked with more than 1,000 hospitals, clinics and medical facilities in the Italian marketplace, Biocommerciale is poised to drive sales of Symmetry Surgical product portfolio.
Since Symmetry Medical’s core Original Equipment Manufacturing (OEM) Solutions business is facing declining capital spending and procedural and pricing pressure from the weak global orthopedic market, the company is focused on expanding its smaller Symmetry Surgical business.
Earlier this month, Symmetry signed a distribution agreement with a leading medical device distributor, MTG Medical Technologies (MTG). Per the terms of the deal, MTG will distribute Symmetry Surgical’s surgical instruments product portfolio in Europe.
Earlier, in October, Symmetry Surgical had entered into a distribution agreement with Canada-based AMT Electrosurgery Inc. to distribute its entire portfolio of medical devices in Canada. In June, Symmetry Surgical had completed a distribution agreement with Japan Surgical Specialty (JSS) Corporation to sell its products in the Japanese market. The company had also completed a distribution agreement to directly distribute its offerings in Australia and New Zealand.
With a clouded orthopedic space in the domestic market, the distribution agreements might be an attempt to diversify the company’s geographical base by exploring offshore opportunities. It should also enable Symmetry to gain a competitive edge against larger players in the market who continue to improve supply continuum.
In the third quarter 2012, Symmetry Surgical revenues jumped 136.1% on a year-over-year basis to gross $24.8 million. Growth was primarily led by contributions from Codman and Olsen Medical buyout (in 2011). The company’s distribution efforts should further boost revenues in the future.
Symmetry is the largest original equipment manufacturer (OEM) and provider of implants and related surgical instruments and cases to orthopedic devices manufacturers. Its major customers include Johnson & Johnson’s (JNJ - Analyst Report) DePuy, Stryker (SYK - Analyst Report) and Zimmer Holdings (ZMH - Analyst Report).
Symmetry currently retains a Zacks #2 Rank, which translates into a short-term Buy rating. However, we maintain our long-term ‘Neutral’ recommendation on the stock.
Get the full Analyst Report on SYK - FREE
Get the full Analyst Report on ZMH - FREE
Get the full Analyst Report on SMA - FREE
Get the full Analyst Report on JNJ - FREE